Curriculum

León Darío Ortíz Gómez

MD.MSc.PhD(c)

ABOUT ME

Current Jobs

Professor:

Neurosurgery Service, University of Antioquia, Medellín
Department of Neurology, Nueva Granada Military University, Bogota
Neuro-oncology Service, CES University, Medellín

Consultation and hospitalization:

Neurologist-Oncologist of the Instituto de Cancerología S.A Medellín
Neurologist at the Las Américas Clinic, Medellín.

Executive Director of the Latin American Network of Neuro-Oncology (Redlano.com)

EDUCATION AND ACADEMY

Studies

Undergraduate studies and title of Doctor and Surgeon:
Universidad Pontificia Bolivariana, Medellin

Specialties:

Internal Medicine, Universidad Pontificia Bolivariana, Medellín
Clinical Neurology, Nueva Granada Military University, Central Military Hospital, Bogotá. - Medal Award for Best Resident
Clinical Oncology, Colombian School of Medicine, El Bosque University, Bogotá

Masters

Master in Epidemiology, Universidad CES, Medellín
Master in Molecular Biology of Cancer, CNIO, Madrid Rotation at the Center for Biological Research (CNIO), Madrid - It is clarified that it does not have a university endorsement in Colombia

Subspecialty

Specialist in Training in Neuro-oncology of the Instituto Nacional de Cancerologia (INC), Bogota
- It is clarified that this training has no university endorsement, only that of the INC

Actual studies:

Second year Bioethics Master's student, CES University
PhD student in Health Sciences-Pharmacogenomics, Fourth year, in course of qualification exam, CES University
English student, level B2.2, CES University, Medellin

my experience

Areas of Interest and Publications:

Personalized diagnosis in glioblastoma

Genotyping Hispanics (1)

Cardona AF, Rojas L, Wills B, Behaine J, Jiménez E, Hakim F, et al. Genotyping low-grade gliomas among Hispanics. Neuro-Oncol Pract. 2016 Sep 1;3(3):164–72.

Personalized diagnosis in glioblastoma

LGG molecular profile in Colombia(2)

Cardona A, Jimenez E, Hakim F, Useche N, Bermudez S, Arrieta O, et al. BI-05 * MOLECULAR PROFILING OF LOW GRADE GLIOMAS (LGG) IN COLOMBIA (ONCOLGROUP). Neuro-Oncol. 2014 Nov 1;16(suppl 5):v24–v24.

Personalized diagnosis in glioblastoma

New genetic biomarkers(3)

Barrera Arenas LM, Restrepo Atehortúa J, Ortiz LD, Camargo Guerrero M. Búsqueda de nuevos biomarcadores genéticos en gliomas de alto grado. Actual Biológicas [Internet]. 2020 Feb 26 [cited 2020 Oct 27];41(111). http://aprendeenlinea.udea.edu.co/revistas/index.php/actbio/article/view/341270

Personalized diagnosis in glioblastoma

Flow cytometry in reticulocytes(4)

Barrera LM, Ortiz LD, Grisales H, Rojas M, Camargo M. Citometría de flujo en reticulocitos de sangre periférica como indicador de inestabilidad cromosómica en pacientes con gliomas de alto grado. Biomédica. 2018 Sep 1;38(3):379–87.

Personalized diagnosis in glioblastoma

Stem cells (5)

Felipe Cardona A, Balana C, Torres D, Becerra H, Dario Ortiz L, E. Fadul C. Stem Cells in Brain Tumorigenesis and their Impact on Therapy. Curr Stem Cell Res Ther. 2011 Dec 1;6(4):339–49.

Areas of Interest and Publications:

Treatment of glioblastoma

Levetiracetam in glioblastoma (6)

Cardona AF, Rojas L, Wills B, Bernal L, Ruiz-Patiño A, Arrieta O, et al. Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma. J Neurooncol. 2018 Jan;136(2):363–71.

Treatment of glioblastoma

Carmustine and bevacizumab in recurrent gliomas (7)

Cardona AF, Rojas L, Wills B, Ruiz-Patiño A, Abril L, Hakim F, et al. A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma. Clin Transl Oncol. 2019 Oct;21(10):1364–73.

Areas of Interest and Publications:

Pituitary

65 years of the double helix

First in the world to use temozolomide in aggressive pituitary adenomas (8)

Syro LV, Rotondo F, Ortiz LD, Kovacs K. 65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update. Endocr Relat Cancer. 2018 Aug;25(8):T159–69

Pituitary

Collaborator of the European Society of Endocrinology (ESE)(9)

McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, et al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol. 2018 Mar;265–76.

Pituitary

Autophagy(10)

Weckman A, Di Ieva A, Rotondo F, Syro LV, Ortiz LD, Kovacs K, et al. Autophagy in the endocrine glands. J Mol Endocrinol. 2014 Apr;52(2):R151–63

Pituitary

GH Pathology(11)

Syro LV, Rotondo F, Serna CA, Ortiz LD, Kovacs K. Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary. Pituitary. 2017 Feb;20(1):84–92.

Pituitary

MEN-1(12)

Syro L, Scheithauer B, Kovacs K, Toledo R, Londoño F, Ortiz L, et al. Pituitary tumors in patients with MEN1 syndrome. Clinics. 2012 Apr 24;67(S1):43–8.

Pituitary

Temozolomide aggressive adenomas (13)

Ortiz L, Syro L, Scheithauer B, Rotondo F, Uribe H, Fadul C, et al. Temozolomide in aggressive pituitary adenomas and carcinomas. Clinics. 2012 Apr 24;67(S1):119–23.

Pituitary

In prolactinoma(14–16)

Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE, Horvath E, et al. Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf). 2006 Oct;65(4):552–3.

Pituitary

In prolactinoma (15)

Kovacs K, Horvath E, Syro LV, Uribe H, Penagros LC, Ortiz LD, et al. Erratum to “Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings.” Hum Pathol. 2007 Mar;38(3):526.

Pituitary

In prolactinoma (16)

Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD, et al. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol. 2007 Jan;38(1):185–9.

Pituitary

In corticotropic(17)

Moshkin O, Syro L, Scheithauer B, Ortiz L, Fadul C, Uribe H, et al. Aggressive silent corticotroph adenoma progressing to pituitary carcinoma. The role of temozolomide therapy. HORMONES. 2011 Apr 15;10(2):162–7.

Pituitary

In gonadotrophics (18)

yro L, Scheithauer B, Ortiz L, Fadul C, Horvath E, Rotondo F, et al. Effect of Temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma. HORMONES. 2009 Oct 15;8(4):303–6.

Pituitary

Non-uniform response (19)

Ersen A, Syro LV, Penagos LC, Uribe H, Scheithauer BW, Ortiz LD, et al. Non-uniform Response to Temozolomide Therapy in a Pituitary Gonadotroph Adenoma. Can J Neurol Sci J Can Sci Neurol. 2012 Sep;39(5):683–5.

Pituitary

Review of temozolomide in pituitary tumors (20)

Syro LV, Rotondo F, Camargo M, Ortiz LD, Serna CA, Kovacs K. Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions. Front Endocrinol [Internet]. 2018 Jun 15 [cited 2020 Jan 18];9. Available from: https://www.frontiersin.org/article/10.3389/fendo.2018.00318/full

Pituitary

Review of temozolomide in treatment(21)

Syro LV, Ortiz LD, Scheithauer BW, Lloyd R, Lau Q, Gonzalez R, et al. Treatment of pituitary neoplasms with temozolomide: A review. Cancer. 2011 Feb 1;117(3):454–62.

Pituitary

MGMT predicts (22)

Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, et al. MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol (Berl). 2008 Feb;115(2):261–2.

Pituitary

Sellar sarcoma(23)

Manoranjan B, Syro LV, Scheithauer BW, Ortiz LD, Horvath E, Salehi F, et al. Undifferentiated Sarcoma of the Sellar Region. Endocr Pathol. 2011 Sep;22(3):159–64.

Pituitary